Keywords
How to Cite
Abstract
Background: Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, a clinically and molecularly diverse group of cancers. DLBCL is difficult to diagnose and treat because of its fast development and the tendency for extranodal involvement.
Aim: The primary aim of this study is to add to the expanding landscape of DLBCL research by determining the prevalence of GCB and non-GCB subgroups in the investigated patient population.
Study Design: This is a prospective design study.
Duration and Place of the Study: This study was conducted at the Department of Oncology, Hayatabad Medical Complex, Peshawar between 10th October 2022 and 10th September 2023.
Material and Methods: There were a total of 100 patients. To classify patients into germinal center B cell (GCB) and non-GCB subtypes, diagnostic samples were exposed to a variety of immune-histochemical testing, including markers such as CD10, Bcl-6, and MUM1.
Results: This study involved 100 patients with DLBCL, with an average age of 58.4±12.6 years. 60% were male 40% were female, and 25% had B symptoms such as fever, night sweats, and weight loss. 70% of patients exhibited extranodal involvement, suggesting that the disease had gone beyond the lymph nodes. A considerable majority of patients had previously had treatment, with 40% receiving chemotherapy and 15% receiving radiation.
Conclusion: The present study offers a detailed examination of the demographic and clinical attributes of patients diagnosed with DLBCL, together with an analysis of the distribution of DLBCL subtypes and their correlation with clinical factors.
References
Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Diffuse large B-cell lymphoma. Critical reviews in oncology/hematology. 2013;87(2):146-71.
Zanelli M, Sanguedolce F, Zizzo M, Fragliasso V, Broggi G, Palicelli A, Loscocco GG, Cresta C, Caprera C, Corsi M, Martino G. Skin Involvement by Hematological Neoplasms with Blastic Morphology: Lymphoblastic Lymphoma, Blastoid Variant of Mantle Cell Lymphoma and Differential Diagnoses. Cancers. 2023;(15):3928.
Berendsen MR, Stevens WB, van den Brand M, van Krieken JH, Scheijen B. Molecular genetics of relapsed diffuse large B-cell lymphoma: insight into mechanisms of therapy resistance. Cancers. 2020 ;12(12):3553.
Di Rocco A, De Angelis F, Ansuinelli M, Foà R, Martelli M. Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?. Expert review of hematology. 2017;10(9):761-74.
Nesic M, El-Galaly TC, Bøgsted M, Pedersen IS, Dybkær K. Mutational landscape of immune surveillance genes in diffuse large B-cell lymphoma. Expert Review of Hematology. 2020;13(6):655-68.
Sorigue M, Kuittinen O. Controversies in the Front-Line Treatment of Systemic Peripheral T Cell Lymphomas. Cancers. 2022;(1):220.
Hori D, Kobayashi R, Nakazawa A, Iwafuchi H, Klapper W, Osumi T, Ohk K, Sekimizu M. Non‐germinal center B‐cell subtype of pediatric diffuse large B‐cell lymphoma in Japan: A retrospective cohort study. Pediatric Blood & Cancer. 2023;(5):e30279.
Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, Shi X, Hans CP, Greiner TC, Bierman PJ, Bociek RG, Armitage JO. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell–like and non–germinal center B-cell–like subtypes of diffuse large B-cell lymphoma. Journal of Clinical Oncology. 2008;26 (28):4587-94.
Wu G, Keating A. Biomarkers of potential prognostic significance in diffuse large B‐cell lymphoma. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2006;106(2):247-57.
Eertink JJ, Zwezerijnen GJ, Wiegers SE, Pieplenbosch S, Chamuleau ME, Lugtenburg PJ, de Jong D, Ylstra B, Mendeville M, Dührsen U, Hanoun C. Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma. Blood Advances. 2023;7(2):214-23.
Gundersen AE. The Karsh Portraits. GUNDERSEN. 2015.
Ajetunmobi OI, Mandong BM, Adelusola KA, Silas OA. Immunohistochemical profiling of lymphomas in Jos University Teaching Hospital. Jos. International Journal of Health Sciences and Research. 2018;2(8):7-18.
Salas MQ, Climent F, Tapia G, DomingoDomènech E, Mercadal S, Oliveira AC, Aguilera C, Olga G, Moreno Velázquez M, Andrade-Campos M, Encuentra M. Clinicopathologic features and prognostic significance of CD30 expression in de novo diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institution. Biomarkers. 2020; (1):69-75.
Chen W, Houldsworth J, Olshen AB, Nanjangud G, Chaganti S, Venkatraman ES, Halaas J, Teruya-Feldstein J, Zelenetz AD, Chaganti RS. Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas. Blood. 2006 ;107(6):2477-85.
Sandlund JT, Martin MG. Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum. Hematology 2014, the American Society of Hematology Education Program Book. ;2016 (1):589-97.
Rasmussen PK. Diffuse large B‐cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features (Doctoral dissertation, Blackwell Publishing Ltd).
Sánchez LG, Redondo AM, Muñez OB, Sebastián E, Alcoceba M, González M, Martín A, Caballero D. Extranodal and nodal diffuse large B cell lymphoma of the head and neck: two different entities?. Annals of Hematology. 2015:609-16.
Nowakowski GS, Czuczman MS. ABC, GCB, and double-hit diffuse large B-cell lymphoma: does subtype make a difference in therapy selection?. American Society of Clinical Oncology Educational Book. 2015;35(1):e449-57.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Pak-Euro Journal of Medical and Life Sciences